ZTS · Zoetis Inc.
$76.052026-07-21Sector: Healthcare; Industry: Drug Manufacturers - General; Sub-Industry: Pharmaceuticals
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$108
+42.7% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($100 · $122) Analysts Range ($85 · $160) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $8.5B | — | 37.7% | 20.0% | $2.6B | −$934MM | $1.6B | 7.2% | — | 22.5% | $11.5B | $5.55 | — |
| 2024.Q4 | $8.5B | 0.0% | 37.7% | 20.3% | $2.6B | $279MM | $2.8B | 8.6% | — | 22.7% | $11.1B | $5.55 | — |
| 2025.Q1 | $9.3B | 8.3% | 38.5% | 20.9% | $2.8B | $148MM | $3.0B | 7.6% | — | 24.9% | $11.5B | $5.89 | — |
| 2025.Q4 | $9.3B | 0.0% | 38.5% | 20.4% | $2.8B | −$741MM | $2.1B | 8.5% | — | 23.8% | $12.3B | $5.89 | — |
| 2026.Q1 | $9.5B | 2.7% | 39.4% | 20.1% | $3.0B | −$879MM | $2.1B | 7.4% | — | 24.3% | $12.4B | $6.26 | 8.6 |
| italics below = DCF projection · 10yr Rev CAGR: 4.4% |
| 2027.Q1 | $9.9B | +3.6% | 40.0% | 20.1% | $3.2B | −$460MM | $2.7B | 7.5% | $2.5B | 25.0% | $12.8B | $7.10 | 10.7 |
| 2028.Q1 | $10.3B | +4.3% | 40.0% | 20.1% | $3.3B | −$572MM | $2.7B | 7.6% | $2.3B | 25.1% | $13.4B | $7.41 | 10.3 |
| 2029.Q1 | $10.8B | +5.1% | 40.0% | 20.1% | $3.5B | −$720MM | $2.7B | 7.7% | $2.2B | 25.1% | $14.1B | $7.79 | 9.8 |
| 2030.Q1 | $11.4B | +5.2% | 40.0% | 20.1% | $3.6B | −$782MM | $2.9B | 7.8% | $2.1B | 25.0% | $14.9B | $8.19 | 9.3 |
| 2031.Q1 | $11.9B | +4.5% | 40.0% | 20.1% | $3.8B | −$730MM | $3.1B | 8.0% | $2.1B | 24.9% | $15.6B | $8.56 | 8.9 |
|
| Term. Yr+ | $15.2B | 4.1% | 31.5% | 20.0% | $3.8B | −$791MM | $3.0B | 8.6% | $31.4B | 19.9% | — | — | — |
Active scenario IV: $108 (+42.7% vs market)